Navigation Links
Celator(R) Pharmaceuticals Study Shows CPX-571 Maintains Synergistic Ratio of Irinotecan and Cisplatin to Improve Anti-tumor Activity
Date:10/26/2007

Promising pre-clinical results support advance to clinical study for third combination chemotherapy from Celator based on the company's proprietary

CombiPlex(TM) technology platform.

PRINCETON, N.J., Oct. 26 /PRNewswire/ -- Celator Pharmaceuticals today announced positive results from preclinical studies to evaluate the optimal ratio of irinotecan and cisplatin to deliver synergistic benefit against a range of tumor cell lines in vitro. The study further worked to develop an effective formulation to maintain the optimal ratio of these drugs in vivo. Results were presented this week in a poster presentation at the AACR-NCI- EORTC International Conference on Molecular Targets and Cancer Therapeutics in San Francisco, CA.

In the study, combinations of irinotecan and cisplatin were applied to a panel of 20 human and murine tumor cell lines enriched with lung tumor carcinomas in vitro to identify the ratios most likely to deliver synergistic benefit. The combination exhibited strong drug ratio dependent synergy. Using Celator's proprietary CombiPlex technology, researchers then engineered a combination of irinotecan and cisplatin in liposomes to maintain a synergistic 7:1 molar ratio following intravenous administration. The product, known as CPX-571, was compared to a combination of irinotecan and cisplatin administered as free drugs, and to monotherapy with each drug agent administered in a liposome formulation in mice implanted with human solid tumor xenografts. In all tumor models tested, CPX-571 showed a high degree of anti-tumor activity and significantly improved efficacy as compared to the combination of free drugs and to the individual liposomal drug agents.

"In this study we were able to identify the optimal ratio of irinotecan and cisplatin to use in combination chemotherapy and then combine the drugs in a formulation able to maintain that ratio in animal models. Along with our progress in developing CPX-1, curre
'/>"/>

SOURCE Celator Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Antibodies for Studying NMDA Receptor Protein Expression and Synapse-Specific Immunolabeling
4. Optimizing Transfection Conditions for Studying Signal Transduction Pathways
5. Enzyme Immunoassay for Studying Intracellular Levels of cAMP
6. RT-PCR Primers for the Study of Apoptosis
7. A Comparison Study of Lipid Tranfection Reagents in A549, NIH 3T3 and COS-7 Cell Lines
8. New Reporter Plasmids for Studying Interferon-Stimulated Signal Transduction Pathways
9. New Fusion Trans-Activator Plasmids for Studying Signal Transduction Pathways
10. Medical College receives $377K to study brain disease
11. Kauffman study shows consistent entrepreneurial growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... According to a new market ... - Global Industry Analysis, Size, Share, Growth, Trends and ... USD 88.5 million in 2011, which is expected to ... CAGR of 53.8% from 2013 to 2023. ... Increasing demand for energy efficient displays ...
(Date:7/31/2014)... 31, 2014 Graphite Metallizing Corporation announces ... oven carts. These bearings are uniquely suited to prevent ... bearings because of the high temperatures . , ... from the design engineers at Graphite Metallizing to overcome ... During their manufacturing operation, pans containing blocks of powder ...
(Date:7/31/2014)... 2014 According to a new ... Medical Devices Market (Diagnostic Electrodes - ECG, EEG, EMG, ... Pacemakers, Defibrillators, Electrosurgical and Other Electrodes) - Global Industry ... 2019," the global electrodes market for medical devices was ... estimated to reach a market worth USD 1,451.2 million ...
(Date:7/31/2014)... Francisco, California (PRWEB) July 31, 2014 ... systems that inform therapeutic decision-making in oncology, today announced ... August 14, 2014 to discuss the Company's financial results ... provide an update about the business in the current ... audio call beginning on Thursday, August 14, 2014, at ...
Breaking Biology Technology:Global Quantum Dots Market is Expected to Reach USD 8,246.8 Million in 2023: Transparency Market Research 2Global Quantum Dots Market is Expected to Reach USD 8,246.8 Million in 2023: Transparency Market Research 3Global Quantum Dots Market is Expected to Reach USD 8,246.8 Million in 2023: Transparency Market Research 4Graphite Metallizing Announces Bearings for High Temperature Oven Applications 2Graphite Metallizing Announces Bearings for High Temperature Oven Applications 3Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 2Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 3Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 4Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 5Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 6CollabRx, Inc. Schedules First Quarter Fiscal Year 2015 Financial Conference Call and Business Update 2
... July 17 Arbel Medical, an Israeli,start-up developing the ... (cryotherapy), has completed raising $4.5 million of,capital in its ... The Docor International investment company, of the Van ... investors who include Giza,Venture Capital, Ofer High Tech, the ...
... ... Follow-On Biologics, RICHMOND, Va., July 17 ... unmet,medical needs, today announced that The Honorable Bill Thomas, Former,Chairman of ... been,retained by Insmed as a strategic advisor to assist the Company,s ...
... Ardea Biosciences, Inc.,(Nasdaq: RDEA ) today announced ... and Westminster Hospital, will present results from the,Phase ... oral,presentation at a late breaker session of the ... 7, 2008. RDEA806 is the Company,s novel,investigational non-nucleoside ...
Cached Biology Technology:Arbel Medical has Completed a $4.5 million Round of Capital Raising led by Giza Venture Capital Fund 2Arbel Medical has Completed a $4.5 million Round of Capital Raising led by Giza Venture Capital Fund 3Insmed Partners With Bill Thomas, Former House Ways and Means Chairman, as Strategic Advisor 2Insmed Partners With Bill Thomas, Former House Ways and Means Chairman, as Strategic Advisor 3Insmed Partners With Bill Thomas, Former House Ways and Means Chairman, as Strategic Advisor 4Ardea to Present Data on Lead HIV Candidate, RDEA806, at XVII International AIDS Conference 2Ardea to Present Data on Lead HIV Candidate, RDEA806, at XVII International AIDS Conference 3
(Date:7/31/2014)... found that bacteria in the Gulf of Mexico consumed ... during the Deepwater Horizon spill in the months after ... In two new studies conducted in a deep sea ... bacteria called Colwellia likely consumed gaseous hydrocarbons ... were released as part of the oil spill. ...
(Date:7/31/2014)... Brazil nuts, cashews, hazelnuts, macadamias, pecans, pine nuts, pistachios ... British Medical Journal Open (BMJ Open) (i) ... Open article looked at the effects of tree ... tree nut consumption resulted in a significant decrease in ... article focused on the effect of tree nuts ...
(Date:7/30/2014)... David L. Kaplan, Ph.D., will head the brand-new, web-only ... editor-in-chief. With the first issue slated for publication in ... in the rapidly burgeoning field of biomaterials, the study ... living or biological systems. , "This new journal is ... field of biomaterials over the past decade and the ...
Breaking Biology News(10 mins):New international tree nut council study looks at nuts, diabetes and metabolic syndrome 2ACS Biomaterials Science & Engineering: Brand-new journal launches in 2015, names editor 2
... Protozoa May Enable Food-Borne Pathogens on Leafy Vegetables ... may sequester harmful food-borne pathogens ultimately contributing to ... Tennessee Technological University, Cookeville and the Produce Safety ... report their findings in the April 2008 issue ...
... Conference, jointly organized by the European Society for Medical ... of Lung Cancer (IASLC) in Geneva, Switzerland highlight emerging ... of lung cancer. Experts agree that smoking ... to lung cancer development. But other factors can play ...
... is a giant among viruses and needs a special strategy ... Helenius and Postdoc Jason Mercer from ETH Zurichs Institute for ... process, they stumbled upon new and surprising findings. ... a cell, the vaccinia virus exploits the cellular waste disposal ...
Cached Biology News:Tips from the Journals of the American Society for Microbiology 2Tips from the Journals of the American Society for Microbiology 3Tips from the Journals of the American Society for Microbiology 4Viruses may play a role in lung cancer development 2A step forward in virology 2A step forward in virology 3
...
... Rhesus serum is collected from fasted Rhesus monkeys ... Available Anticoagulants: N-02: ... K2EDTA N-08: Potassium Oxalate ... N-05: ACD N-07: CPD ...
Collected from sexually mature, mixed sex, mixed breed guinea pigs. Pricing: $120/unit for 1 - 10 units...
Active GST Protein...
Biology Products: